Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention

Recruiting now · Phase 4

Conditions studied: Deep Venous Thromboses, Laparotomy Patients

In brief

The goal of this clinical trial is to learn if rivaroxaban works better than enoxaparin to prevent deep vein thrombosis (DVT) after emergency exploratory laparotomy in adults. It will also learn about the safety of rivaroxaban compared to enoxaparin. The main questions it aims to answer are: Does rivaroxaban lower the number of patients who develop DVT after exploratory laparotomy compared to enoxaparin? What medical problems or side effects do participants have when taking rivaroxaban versus enoxaparin? Researchers will compare rivaroxaban (an oral anticoagulant) to enoxaparin (a subcutaneous injection) to see which drug works better to prevent blood clots after surgery. Participants will: Take rivaroxaban 10 mg orally once daily for 7 days, or enoxaparin 40 mg subcutaneously once daily for 7 days after surgery Undergo duplex color Doppler ultrasound scans of the legs on day 5 and day 10 after surgery Be monitored for bleeding, complications, and other side effects

Key facts

Study ID: NCT07243080
Run by: Mayo Hospital Lahore
People needed: 212
Starts: 2025-10-10
Expected to finish: 2025-11-15
Last updated by the study team: 2025-11-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Patients with diagnosed pre-operative DVT
BMI more than 40
Patient who are on mechanical ventilation post operatively
Patient with postoperative Myocardial infarction, ischemic heart disease or cerebrovascular accident
Patients who have undergone limb surgery in addition to exploratory laparotomy

Where it is running

Mayo Hospital Lahore — Lahore, Punjab Province, Pakistan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.